CA2066313C - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number: CA2066313C
Authority: CA; Canada
Prior art keywords: pharmaceutical composition; compositions; methyl; glioma; treatment
Prior art date: 1991-10-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002066313A

Other languages

English (en)

Other versions

CA2066313A1 (fr

Inventor

Malcolm Francis Graham Stevens

Edward Stuart Newlands

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cancer Research Campaign Technology Ltd

Original Assignee

Cancer Research Campaign Technology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-18

Filing date

1992-04-16

Publication date

2002-08-20

1991-10-18 Priority claimed from US07/781,020 external-priority patent/US5260291A/en

1992-04-16 Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd

1993-04-19 Publication of CA2066313A1 publication Critical patent/CA2066313A1/fr

2002-08-20 Application granted granted Critical

2002-08-20 Publication of CA2066313C publication Critical patent/CA2066313C/fr

2012-04-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 3
208000032612 Glial tumor Diseases 0.000 claims abstract description 7
206010018338 Glioma Diseases 0.000 claims abstract description 7
201000005962 mycosis fungoides Diseases 0.000 claims abstract description 4
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 4
239000011248 coating agent Substances 0.000 claims 1
238000000576 coating method Methods 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 12
239000000203 mixture Substances 0.000 description 10
239000000243 solution Substances 0.000 description 5
206010017533 Fungal infection Diseases 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
208000024386 fungal infectious disease Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
244000046052 Phaseolus vulgaris Species 0.000 description 2
235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000010445 mica Substances 0.000 description 2
229910052618 mica group Inorganic materials 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241001116389 Aloe Species 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101100010135 Halomonas elongata (strain ATCC 33173 / DSM 2581 / NBRC 15536 / NCIMB 2198 / 1H9) doeB gene Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001139947 Mida Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101150097527 PARN gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
240000002825 Solanum vestissimum Species 0.000 description 1
235000018259 Solanum vestissimum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
238000005266 casting Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 1
229950005967 mitozolomide Drugs 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002066313A 1991-10-18 1992-04-16 Composition pharmaceutique Expired - Lifetime CA2066313C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/781020		1991-10-18
US07/781,020 US5260291A (en)	1981-08-24	1991-10-18	Tetrazine derivatives

Publications (2)

Publication Number	Publication Date
CA2066313A1 CA2066313A1 (fr)	1993-04-19
CA2066313C true CA2066313C (fr)	2002-08-20

Family

ID=25121424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002066313A Expired - Lifetime CA2066313C (fr)	1991-10-18	1992-04-16	Composition pharmaceutique

Country Status (1)

Country	Link
CA (1)	CA2066313C (fr)

1992
- 1992-04-16 CA CA002066313A patent/CA2066313C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2066313A1 (fr)	1993-04-19

Similar Documents

Publication	Publication Date	Title
US5985876A (en)	1999-11-16	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
EP0226266B1 (fr)	1996-02-28	Utilisation d'un dérivé du tétrahydrocarbazolone pour la fabrication de médicaments
EP1104297B1 (fr)	2006-01-11	Compositions pour le traitement de la leucemie lymphocitaire chronique
EP1478355B1 (fr)	2007-03-07	Compositions antitumorales contenant des derives de taxane
US6403563B1 (en)	2002-06-11	Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
KR20010033028A (ko)	2001-04-25	막-관련 바이러스 복제의 억제
US4980344A (en)	1990-12-25	Compositions for improving circulatory performance
CA1326441C (fr)	1994-01-25	Compositions pharmaceutiques ayant une activite anti-cancereuse et methode de traitement du cancer
PL198185B1 (pl)	2008-06-30	Zastosowanie Ekteinascydyny 743 do wytwarzania kompozycji farmaceutycznej
Burke et al.	1971	Imidazole carboxamide therapy in advanced malignant melanoma
EP0774255A1 (fr)	1997-05-21	Utilisation de l'acide ursolique pour la fabrication d'un médicament pour supprimer des métastases
CA2066313C (fr)	2002-08-20	Composition pharmaceutique
KR100742524B1 (ko)	2007-08-02	캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 약제학적 병용제제
EP0190851A1 (fr)	1986-08-13	Composition anti-inflammatoire
CA2001004C (fr)	1996-01-30	Derives d'ergoline antivomitifs
EP0215200B1 (fr)	1992-09-09	Utilisation des sulfanilamido quinoxalines pour le traitement des maladies néoplastiques
EP0218453A1 (fr)	1987-04-15	Compositions et procédés anti-inflammatoires
EP0975338A2 (fr)	2000-02-02	Derives de 2,2'-bi-1h-pyrrole utilises pour traiter la leucemie provoquee par le virus htlv-1
EP0650726A1 (fr)	1995-05-03	4-piperidino-piperidine pour le traitement du tumeur
US3456057A (en)	1969-07-15	Pharmaceutical compositions and methods utilizing 3-aminotricyclo(4.3.1.1**3.8)undecanes
EP0433682A2 (fr)	1991-06-26	Utilisation de 2,4,5-tri(4-méthoxyphényl)-4,5-dihydroimidazole pour le traitement du cancer
US20040138207A1 (en)	2004-07-15	Antitumor agents
JPH0513133B2 (fr)	1993-02-19
EP0313094B1 (fr)	1993-09-01	Médicament anticancéreux et réactif pour l'obtention des revertants
EP0336275B1 (fr)	1993-08-04	L'utilisation des dérivés du spergualine contre les effets secondaires d'origine radiologique ou médicamenteuse

Legal Events

Date	Code	Title	Description
1998-10-27	EEER	Examination request
2012-04-16	MKEX	Expiry
2023-10-24	MKEX	Expiry	Effective date: 20120416